Building high-rise buildings isn’t child’s play. Master the essentials of soil analysis, deep foundations, and structural ...
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A novel GLP-1 and amylin receptor agonist reduced HbA1c ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIRâ„¢ ...
CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation & immunology (I&I), ...
ATLANTA — Eli Lilly’s investigational weekly amylin receptor agonist eloralintide produced significant weight loss over 48 weeks and was generally well tolerated, particularly with incremental dose ...
The phase 2 trial of FL115 with BCG targets NMIBC patients unsuitable for radical cystectomy, focusing on response and survival metrics. Conducted at 12 sites in China, the trial builds on phase 1 ...
Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC) Forlong Biotechnology, a clinical-stage ...
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...
A new development in Rochester, known as The Ridge phase 2, is planned to include housing, commercial buildings, and a hospital emergency department. Developers are seeking a permit recommendation ...
Rezatapopt demonstrated a 33% overall response rate in tumors with TP53 Y220C mutations, with a median response duration of 6.2 months. The phase 2 PYNNACLE trial reported consistent safety results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback